OS9.1 Clinical significance of hypermutation in gliomas

BACKGROUND: Among patients with glioma, little is known about the clinical significance of hypermutation. We sought to define the determinants of hypermutation in gliomas, and to assess the value of this biomarker for predicting response to standard of care and immune checkpoint blockade. MATERIAL A...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Touat, M, Li, Y, Boynton, A, Spurr, L, Iorglescu, B, Geduldig, J, Birzu, C, Lim Fat, M, Santagata, S, Coulet, F, Beuvon, F, Mokhtari, K, Giry, M, Block, S, Guillerm, E, Carpentier, A, Huang, R, Delattre, J, Hoang-Xuan, K, Sanson, M, Duval, A, Cherniack, A, Reardon, D, Wen, P, Idbaih, A, Marabelle, A, Bandopadhayay, P, Beroukhim, R, Bielle, F, Ligon, K
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Oral Presentations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6795177/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz126.059
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados